Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

2021; Massachusetts Medical Society; Volume: 386; Issue: 6 Linguagem: Inglês

10.1056/nejmoa2116044

ISSN

1533-4406

Autores

Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, E. A. Kovalchuk, Antonio Herrero, Virginia delos Reyes, Alejandro Martín‐Quirós, Yoseph Caraco, Angela Williams‐Diaz, Michelle Brown, Jiejun Du, Alison Pedley, Christopher Assaid, Julie Strizki, Jay A. Grobler, Hala Shamsuddin, Robert Tipping, Hong Wan, Amanda Paschke, Joan R. Butterton, Matthew G. Johnson, Carisa De Anda,

Tópico(s)

COVID-19 Clinical Research Studies

Resumo

New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Referência(s)